NasdaqGM:RNAMBiotechs
Avidity Biosciences (RNA) Posts FY 2025 US$237 Million Loss Challenging Bullish Growth Narratives
Avidity Biosciences (RNA) has wrapped up FY 2025 with fourth quarter revenue of about US$0.9 million, a basic EPS loss of US$1.54 and a net loss of roughly US$237.1 million. Over recent quarters the company has seen revenue move from US$2.3 million in Q3 2024 to US$12.5 million in Q3 2025. Basic EPS shifted from a loss of US$0.65 in Q3 2024 to a loss of US$1.27 in Q3 2025, and trailing 12 month EPS landed at a loss of US$4.97. This sets the stage for a results season where investors are...